Revenue surged 105% year-over-year as three approved products scale globally.

Ascendis Pharma stock has delivered a 5.8% gain year to date, yet current valuation checks and market pricing point to a company that is not clearly cheap at today’s levels. With recent positive clinical updates and index inclusion in the background, the key issue for investors is how much of that optimism is already embedded in the share price. Year to date, Ascendis Pharma is up 5.8%, which suggests recent news and progress are being recognized but not in a runaway rally. Progress across...

Ascendis Pharma earnings and trial updates set the stage Ascendis Pharma (NasdaqGS:ASND) caught investor attention after reporting second quarter 2026 results on August 13, alongside fresh clinical updates on its TransCon CNP programs in growth disorders. The company reported second quarter sales of €339.29 million, with net income of €206.97 million and basic earnings per share from continuing operations of €3.22, based on its latest earnings release. See our latest analysis for Ascendis...

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of

Ascendis Pharma AS (ASND) reports record Q2 2026 results with product revenue more than doubling year-over-year, driven by strong YORVIPATH and YUVIWEL performance.

European equities traded in the US as American depositary receipts were higher late Thursday morning

Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapies continued to increase. Chief Financial Officer Scott Smith said product revenue more than double

European equities traded in the US as American depositary receipts were heading higher late Thursday

European equities traded in the US as American depositary receipts rose late Tuesday morning with th

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The fund reported strong absolute returns and modestly outperformed the Russell 2000® Growth Index, which gained 25.7%. Global equities rebounded as resilient US growth, moderating inflation, strong earnings and […]

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

Ascendis Pharma reported new two-year radiographic outcomes from its pivotal ApproaCH trial of TransCon CNP (YUVIWEL) in children with achondroplasia. The data show continued improvements in lower limb alignment and maintained growth velocity over two years, with treatment generally well tolerated. This update follows recent US approval of TransCon CNP (YUVIWEL) and comes as the therapy remains under regulatory review in Europe. For investors watching Ascendis Pharma (NasdaqGS:ASND), the...

Ascendis Pharma stock has climbed 24.0% over the past month, yet the current valuation checks and market multiples point to a picture that is not clearly cheap or clearly expensive. The 24.0% gain over the past 30 days suggests investors have recently been willing to pay up for Ascendis Pharma, which raises the bar for what the fundamentals need to deliver next. Expectations around Ascendis Pharma's ability to turn its pipeline into sustained revenue growth can support the current share...